Discover Your Eligibility for a New Clinical Trial

Discover if you qualify for the X-TOLE2 clinical trial and take the next step toward innovative care. Sign up today to be matched quickly and easily.

Find Out If You Are a Match for the X-TOLE2 Trial

Through an innovative collaboration with Neuroventis and Embleema, we’ve made it easy for patients to pre-screen and discover if they may qualify for this groundbreaking clinical trial.

If you are a match, you have the opportunity to contribute to significant advancements in medical knowledge and help improve treatments for patients like yourself. Your participation can make a substantial impact on epilepsy healthcare.

Get Started

Home

About Us

Get Matched by Registering on Embleema

Create a Profile: Provide basic health information to get started.

Find a Match: Answer the 'My Epilepsy' questionnaire. Our platform identifies whether you are a match for the clinical trial.

Connect & Enroll: A trial coordinator will get in touch to help you learn more and begin the enrollment process.

Determine Your Eligibility In a Few Steps

After sign-up, answer questions about your epilepsy to be matched. You may qualify for the X-TOLE2 study if you:

Have been diagnosed with focal epilepsy (seizures occurring on only one side of the brain) for 2+ years

Are on a stable dose of 1–3 anti-seizure medications

Have tried at least 2 anti-seizure medications but are still experiencing seizures

Why Participate?

If eligible and enrolled, participants in the study may receive:

Study medication at no cost

Epilepsy-related medical care

Compensation for study visits

Travel expense reimbursements

After the initial screening, your study doctor will explain these benefits in detail and answer any questions about the trial.

About the study team

Neuroventis is a digital health company specializing in neurological care. Their platform enhances patient engagement and remote monitoring, empowering individuals with neurological disorders to actively participate in their treatment. By facilitating seamless communication between patients and healthcare professionals, Neuroventis aims to improve treatment outcomes and advance neurology care.

Embleema, a New York-based healthcare technology company, has partnered with the Epilepsy Foundation to launch BET, a platform that consolidates patient health data, enables secure sharing with caregivers and researchers, and offers personalized insights for improved condition management. Embleema’s platform, trusted by the FDA, NIH, top U.S. health networks, and leading organizations, continues its commitment to empowering the epilepsy community.

Take the next step in advancing epilepsy research and improving your care

Get Started